NEW YORK (GenomeWeb) – InSilixa and DNA Software announced today that they have formed a partnership to develop multiplex infectious disease panels for use on InSilixa's complementary metal-oxide semiconductor, or CMOS, biochip platform.
The CMOS technology enables rapid detection and genotyping of pathogens in clinical samples, as well as simultaneous drug-resistance profiling, using highly-multiplexed targeted DNA sequencing, according to InSilixa. The company is focusing its first generation of biochips on point-of-care infectious disease diagnosis.